Berberine

Graves' Disease—Promising#

The strongest triangle comes from a 6-month controlled clinical trial (n=18) comparing methimazole alone vs. methimazole + berberine (2.7g/day):^{[1]Han et al. 2022 — The Potential Prebiotic Berberine Combined With Methimazole Improved the Therapeutic Effect of Graves' Disease Patients Through Regulating the Intestinal MicrobiomeHan Z, Cen C, Ou Q et al. · 2022Open reference 1 ↓}

I → f (Intervention to feature): Berberine significantly restructured the gut microbiota (Bray-Curtis P=0.013), increasing beneficial Lactococcus (L. lactis) and Enterococcus (E. hirae) while decreasing pathogenic Enterobacter hormaechei.

Critically, berberine upregulated enterobactin biosynthesis—a siderophore pathway essential for iron acquisition—and vitamin K2 biosynthesis pathways.^{[1]Han et al. 2022 — The Potential Prebiotic Berberine Combined With Methimazole Improved the Therapeutic Effect of Graves' Disease Patients Through Regulating the Intestinal MicrobiomeHan Z, Cen C, Ou Q et al. · 2022Open reference 1 ↓}

I → D (Intervention to disease): The combination group restored TSH to the 4.2 IU/L healthy threshold and shifted TRAb toward normal (1.75 IU/mL); methimazole alone only restored FT3. The differences in TSH trajectory were statistically significant.^{[1]Han et al. 2022 — The Potential Prebiotic Berberine Combined With Methimazole Improved the Therapeutic Effect of Graves' Disease Patients Through Regulating the Intestinal MicrobiomeHan Z, Cen C, Ou Q et al. · 2022Open reference 1 ↓}

f → D (Feature to disease): Faecalibacterium prausnitzii and L. lactis were negatively correlated with FT3, FT4, and TRAb but positively correlated with TSH—connecting specific microbial shifts to thyroid function recovery.

The enterobactin-iron-thyroid link is mechanistically coherent: iron is required for thyroid peroxidase (TPO) activity, and improved microbial iron acquisition may support host iron availability for thyroid hormone synthesis.^{[1]Han et al. 2022 — The Potential Prebiotic Berberine Combined With Methimazole Improved the Therapeutic Effect of Graves' Disease Patients Through Regulating the Intestinal MicrobiomeHan Z, Cen C, Ou Q et al. · 2022Open reference 1 ↓}

Limitations: Small sample size (n=8 vs. n=10), non-randomized allocation, high berberine dose (2.7g/day) with unreported GI side effects, and the enterobactin-iron-thyroid causal chain is plausible but not directly demonstrated.

Cross-References#

• Graves' Disease—primary condition with triangle evidence
• Faecalibacterium prausnitzii—key taxon correlated with thyroid recovery
• Lactococcus—increased by berberine; correlated with TSH normalization
• Siderophores—enterobactin upregulation as mechanism
• Iron—enterobactin-iron-thyroid peroxidase connection
• Polyphenols—berberine shares prebiotic mechanisms with other plant alkaloids